Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Cui Y, Song Y, Wang J, et al. Clinical Pharmacology: Advances and Applications. 2013;5(1):177–184.Note that on page 182, Figure 3 should be corrected as follows, with the line for mean anti-Xa activity extended through to 72 hours post dose on Day 9, and the Day 1 plasma apixaban concentr...
Guardado en:
Autores principales: | , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0e4dedde10cd43628941128f1a86ea40 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:0e4dedde10cd43628941128f1a86ea40 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:0e4dedde10cd43628941128f1a86ea402021-12-02T06:30:52ZSingle- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]1179-1438https://doaj.org/article/0e4dedde10cd43628941128f1a86ea402014-03-01T00:00:00Zhttp://www.dovepress.com/single--and-multiple-dose-pharmacokinetics-pharmacodyncorrigendum-a16243https://doaj.org/toc/1179-1438 Cui Y, Song Y, Wang J, et al. Clinical Pharmacology: Advances and Applications. 2013;5(1):177–184.Note that on page 182, Figure 3 should be corrected as follows, with the line for mean anti-Xa activity extended through to 72 hours post dose on Day 9, and the Day 1 plasma apixaban concentration-time profile rendering error bars and symbols more visually apparent.Read the original articleCui YSong YWang JYu ZSchuster ABarrett YCFrost CDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2014, Iss default, Pp 61-62 (2014) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Therapeutics. Pharmacology RM1-950 |
spellingShingle |
Therapeutics. Pharmacology RM1-950 Cui Y Song Y Wang J Yu Z Schuster A Barrett YC Frost C Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum] |
description |
Cui Y, Song Y, Wang J, et al. Clinical Pharmacology: Advances and Applications. 2013;5(1):177–184.Note that on page 182, Figure 3 should be corrected as follows, with the line for mean anti-Xa activity extended through to 72 hours post dose on Day 9, and the Day 1 plasma apixaban concentration-time profile rendering error bars and symbols more visually apparent.Read the original article |
format |
article |
author |
Cui Y Song Y Wang J Yu Z Schuster A Barrett YC Frost C |
author_facet |
Cui Y Song Y Wang J Yu Z Schuster A Barrett YC Frost C |
author_sort |
Cui Y |
title |
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum] |
title_short |
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum] |
title_full |
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum] |
title_fullStr |
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum] |
title_full_unstemmed |
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum] |
title_sort |
single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy chinese subjects [corrigendum] |
publisher |
Dove Medical Press |
publishDate |
2014 |
url |
https://doaj.org/article/0e4dedde10cd43628941128f1a86ea40 |
work_keys_str_mv |
AT cuiy singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT songy singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT wangj singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT yuz singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT schustera singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT barrettyc singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT frostc singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum |
_version_ |
1718399857549377536 |